Your browser doesn't support javascript.
Potent Anti-SARS-CoV-2 Efficacy of COVID-19 Hyperimmune Globulin from Vaccine-Immunized Plasma.
Yu, Ding; Li, Yu-Feng; Liang, Hong; Wu, Jun-Zheng; Hu, Yong; Peng, Yan; Li, Tao-Jing; Hou, Ji-Feng; Huang, Wei-Jin; Guan, Li-Dong; Han, Ren; Xing, Yan-Tao; Zhang, Yong; Liu, Jia; Feng, Lu; Li, Chun-Yan; Liang, Xiao-Long; Ding, Ya-Ling; Zhou, Zhi-Jun; Ji, De-Ming; Wang, Fei-Fei; Yu, Jian-Hong; Deng, Kun; Xia, Dong-Mei; Dong, De-Mei; Hu, Heng-Rui; Liu, Ya-Jie; Fu, Dao-Xing; He, Yan-Lin; Zhou, Dong-Bo; Yang, Hui-Chuan; Jia, Rui; Ke, Chang-Wen; Du, Tao; Xie, Yong; Zhou, Rong; Li, Ce-Sheng; Wang, Man-Li; Yang, Xiao-Ming.
  • Yu D; Chengdu Rongsheng Pharmaceuticals Co. Ltd., Chengdu, 610041, China.
  • Li YF; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Liang H; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Wu JZ; Chengdu Rongsheng Pharmaceuticals Co. Ltd., Chengdu, 610041, China.
  • Hu Y; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Peng Y; Chengdu Rongsheng Pharmaceuticals Co. Ltd., Chengdu, 610041, China.
  • Li TJ; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Hou JF; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Huang WJ; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Guan LD; National Institute for Food and Drug Control of China, Beijing, 102629, China.
  • Han R; National Institute for Food and Drug Control of China, Beijing, 102629, China.
  • Xing YT; National Institute for Food and Drug Control of China, Beijing, 102629, China.
  • Zhang Y; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Liu J; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Feng L; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Li CY; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Liang XL; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Ding YL; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Zhou ZJ; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Ji DM; Chengdu Rongsheng Pharmaceuticals Co. Ltd., Chengdu, 610041, China.
  • Wang FF; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Yu JH; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Deng K; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Xia DM; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Dong DM; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Hu HR; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Liu YJ; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Fu DX; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • He YL; Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, 430071, China.
  • Zhou DB; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Yang HC; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Jia R; Sinopharm Wuhan Plasma-derived Biotherapies Co. Ltd., Wuhan, 430207, China.
  • Ke CW; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Du T; China National Biotec Group Company Limited, Beijing, 100029, China.
  • Xie Y; China National Biotec Group Company Limited, Beijing, 100029, China.
  • Zhou R; Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, 511430, China.
  • Li CS; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Wang ML; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
  • Yang XM; Beijing Tiantan Biological Products Co. Ltd., Beijing, 100024, China.
Adv Sci (Weinh) ; 9(14): e2104333, 2022 05.
Article Dans Anglais | MEDLINE | ID: covidwho-1782562
ABSTRACT
Coronavirus disease 2019 (COVID-19) remains a global public health threat. Hence, more effective and specific antivirals are urgently needed. Here, COVID-19 hyperimmune globulin (COVID-HIG), a passive immunotherapy, is prepared from the plasma of healthy donors vaccinated with BBIBP-CorV (Sinopharm COVID-19 vaccine). COVID-HIG shows high-affinity binding to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein, the receptor-binding domain (RBD), the N-terminal domain of the S protein, and the nucleocapsid protein; and blocks RBD binding to human angiotensin-converting enzyme 2 (hACE2). Pseudotyped and authentic virus-based assays show that COVID-HIG displays broad-spectrum neutralization effects on a wide variety of SARS-CoV-2 variants, including D614G, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Kappa (B.1.617.1), Delta (B.1.617.2), and Omicron (B.1.1.529) in vitro. However, a significant reduction in the neutralization titer is detected against Beta, Delta, and Omicron variants. Additionally, assessments of the prophylactic and treatment efficacy of COVID-HIG in an Adv5-hACE2-transduced IFNAR-/- mouse model of SARS-CoV-2 infection show significantly reduced weight loss, lung viral loads, and lung pathological injury. Moreover, COVID-HIG exhibits neutralization potency similar to that of anti-SARS-CoV-2 hyperimmune globulin from pooled convalescent plasma. Overall, the results demonstrate the potential of COVID-HIG against SARS-CoV-2 infection and provide reference for subsequent clinical trials.
Sujets)
Mots clés

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Vaccins contre la COVID-19 / COVID-19 / Globulines Type d'étude: Étude pronostique Les sujets: Vaccins / Variantes Limites du sujet: Animaux / Humains langue: Anglais Revue: Adv Sci (Weinh) Année: 2022 Type de document: Article Pays d'affiliation: Advs.202104333

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: Vaccins contre la COVID-19 / COVID-19 / Globulines Type d'étude: Étude pronostique Les sujets: Vaccins / Variantes Limites du sujet: Animaux / Humains langue: Anglais Revue: Adv Sci (Weinh) Année: 2022 Type de document: Article Pays d'affiliation: Advs.202104333